Diffuse large B-cell lymphoma
Drug research and approvals for diffuse large B-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 298 studies of diffuse large B-cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 56 drug trials for it since 2013, FDA has 19 approved and 16 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 298
- Trials authorized in Canada: 56
- FDA orphan approvals: 19
- EU medicines: 6
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 10, 2026
- Prospective ctDNA Testing in Large B-Cell LymphomaNCT07878351 · Not reported · Peking University People's Hospital · starts Oct 15, 2026
- Proton Therapy for Mediastinal Lymphoma (PROMLY)NCT07817641 · Not applicable · Copenhagen University Hospital, Rigshospitalet · starts May 1, 2026
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus…NCT07808827 · Phase 3 · Shanghai Junshi Bioscience Co., Ltd. · starts Oct 8, 2026
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory…NCT07788118 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 1, 2026
- CD38 Targeted -PET/ CT for Multiple MyelomaNCT07782944 · Not applicable · Guilin Medical University, China · starts Jul 7, 2026
- Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLNCT07778212 · Not applicable · The First Affiliated Hospital of Xiamen University · starts Aug 30, 2026
Approved 9
- Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chain binding agent
- TafasitamabB-lymphocyte antigen CD19 binding agent
- GlofitamabB-lymphocyte antigen CD20 binding agent
- Axicabtagene ciloleucelB-lymphocyte antigen CD19 binding agent
- Loncastuximab tesirineB-lymphocyte antigen CD19 binding agent
- TisagenlecleucelB-lymphocyte antigen CD19 binding agent
- SelinexorExportin-1 inhibitor
- EpcoritamabB-lymphocyte antigen CD20 binding agent
- VinblastineTubulin inhibitor
Phase 3 12 of 58
- RituximabB-lymphocyte antigen CD20 binding agent
- CyclophosphamideDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- DoxorubicinDNA topoisomerase II alpha inhibitor
- VincristineTubulin inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CytarabineDNA inhibitor
- OxaliplatinDNA inhibitor
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- ZanubrutinibTyrosine-protein kinase BTK inhibitor
- IfosfamideDNA inhibitor
Phase 2 12 of 76
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- BlinatumomabT cell surface glycoprotein CD3 cross-linking agent
- BusulfanDNA inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- PanobinostatHistone deacetylase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- BelinostatHistone deacetylase inhibitor
- CopanlisibPI3-kinase p110-alpha subunit inhibitor
Phase 1 or earlier 12 of 57
- Carfilzomib26S proteasome inhibitor
- Avadomide
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- ZandelisibPI3-kinase p110-delta subunit inhibitor
- OnatasertibSerine/threonine-protein kinase mTOR inhibitor
- AlisertibSerine/threonine-protein kinase Aurora-A inhibitor
- TanespimycinHeat shock protein HSP90 inhibitor
- VistusertibSerine/threonine-protein kinase mTOR inhibitor
- TazemetostatHistone-lysine N-methyltransferase EZH2 inhibitor
- ParsaclisibPI3-kinase p110-delta subunit inhibitor
- IrinotecanDNA topoisomerase I inhibitor
How its trials ended
1,282 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 353 whose ending is known, 34% met their primary endpoint, 6% missed it and 60% stopped early.
- Ongoing43534%
- Completed, result not reported33826%
- Status unknown15612%
- Met its primary endpoint1199%
- Stopped: other or unclear867%
- Stopped: sponsor or business decision504%
- Stopped: enrollment or feasibility423%
- Missed its primary endpoint222%
- Stopped: lack of efficacy202%
- Stopped: funding111%
- Stopped: safety3<1%
| Oct 30, 2026 | A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cell…MK-1045 / Zilovertamab vedotin (MK-2140) | Merck & Co. (MSD) | Pending |
| Oct 16, 2026 | A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 × ANTI-CD3 bispecific antibody, in…Odronextamab (REGN1979) | Regeneron | Pending |
| Jun 20, 2025 | An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /… | Treeline Biosciences | Ongoing |
| Dec 13, 2024 | A randomized, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with r-chp versus r-chop in participants with previously…Zilovertamab vedotin (MK-2140) / Rituximab / Cyclophosphamide / Doxorubicin /… | Merck & Co. (MSD) | Ongoing |
| Jul 10, 2024 | A prospective, multicenter, phase II trial to evaluate the efficacy of zanubrutinib and tislelizumab as well as standard of care for the treatment of patients…Zanubrutinib (BGB3111) / Tislelizumab (BGB-A317) | Dr. John Kuruvilla, University Health Network | Ongoing |
| Apr 30, 2024 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus r-chop chemotherapy vs placebo…Golcadomide (BMS-986369, CC-99282)/ Rituximab/ Cyclophosphamide/ Doxorubicin/… | Bristol-Myers Squibb | Ongoing |
| Feb 23, 2024 | Feasibility trial of glofitamab in a response adapted approach incorporating interim fdg pet and ctdna to optimize primary therapy of DLBCL (GRAIL)Columvi / Actemra / Avtozma / Tyenne | Dr. John Kuruvilla, University Health Network | Ongoing |
| Nov 7, 2023 | Optimizing lymphodepletion to improve outcomes in patients receiving ANTI-CD19 car t cell therapy with kymriah/tisagenlecleucel (LOKI)Fludarabine / Cyclophosphasmide | University Health Network | Closed |
| Jul 19, 2023 | A multi-center single arm phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing ANTI-CD20 and ANTI-CD19…MB-CART2019.1 (zamtocabtagene autoleucel) | Miltenyi Biomedicine, GmbH | Ongoing |
| Jul 6, 2023 | A phase III, multicenter, randomized, open label study comparing the efficacy and safety of glofitamab (RO7082859) in combination with polatuzumab vedotin plus…Columvi / Polivy / Actemra (foreign-market source) / Rituxan | Roche | Ongoing |
| Feb 5, 2026 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Apr 19, 2023 | PolivyIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have… | Genentech, Inc. | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jun 24, 2022 | BreyanziTreatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Apr 1, 2022 | YescartaTreatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12… | Kite Pharma, Inc. | Approved |
| Dec 2, 2021 | RituxanTreatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell… | Genentech, Inc. | Approved |
| Apr 23, 2021 | ZynlontaTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | ADC Therapeutics SA | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Feb 5, 2021 | BreyanziTreatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Jul 31, 2020 | MonjuviMONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell… | Incyte Corporation | Approved |
| Jun 22, 2020 | XpovioXPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise… | Karyopharm Therapeutics, Inc. | Approved |
| Jun 10, 2019 | PolivyPOLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or… | Genentech, Inc. | Approved |
| May 1, 2018 | KymriahKYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed… | Novartis Pharmaceuticals Corporation | Approved |
| Sep 22, 2023 | TepkinlyEpcoritamab | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 7, 2023 | ColumviGlofitamab | Roche Registration GmbH | EMA ↗ |
| Dec 20, 2022 | ZynlontaLoncastuximab tesirine | Swedish Orphan Biovitrum AB | EMA ↗ |
| Apr 4, 2022 | BreyanziLisocabtagene maraleucel | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Aug 26, 2021 | MinjuviTafasitamab · orphan | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Jan 16, 2020 | PolivyPolatuzumab vedotin · orphan | Roche Registration GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA